Search

This research was aimed to study and analyze the impact of the shocks of the agricultural net terms of trade (NBTT) on agricultural product (AP) in Iraq during the period (1990 – 2021), which are among the shocks affecting the agricultural sector and foreign trade, the research used quantitative approaches in estimating the levels of impact, including VAR model, variance decomposition analysis (VDA) and impulse response function (IRF). The results showed that VDA of AP was weak in respect of agricultural NBTT and vice versa. While IRF of NBTT was negative in respect of Ap, and the same result was for IRF of AP. The study recommended the need to consider strategies to support smallholder farmers, such as providing access to credit, soft loans, technical assistance and markets for their products, in addition of support the technological advancements for their role in shaping the relationship between agricultural trade and agricultural production.

In this paper voltage stability is analysed based not only on the voltage deviations from the nominal values but also on the number of limit violating buses and severity of voltage limit violations. The expression of the actual state of the system as a numerical index like severity, aids the system operator in taking better security related decisions at control centres both during a period of contingency and also at a highly stressed operating condition. In contrary to conventional N – 1 contingency analysis, Northern Electric Reliability Council (NERC) recommends N – 2 line contingency analysis. The decision of the system operator to overcome the present contingency state of the system must blend harmoniously with the stability of the system. Hence the work presents a novel N – 2 contingency analysis based on the continuous severity function of the system. The study is performed on 4005 possible combinations of N – 2 contingency states for the practical Indian Utility 62 bus system. Static VAr Compensator is used to improve voltage profile during line contingencies. A multi- objective optimization with the objective of minimizing the voltage deviation and also the number of limit violating bus with optimal location and optimal sizing of SVC is achieved by Particle Swarm Optimization algorithm.

Introduction Currently, there are no guidelines for the management of locally advanced unresectable or metastatic urothelial carcinoma (mUC) from an Indian perspective. There is a lack of consensus on the utility of treatment options in firstline (1L) and second-line (2L) settings, especially in cisplatin- and platinum-unfit mUC patient subgroups. Objective This articles aims to develop evidence-based practical consensus recommendations for the management of mUC in Indian settings. Methods Modified Delphi consensus methodology was considered to arrive at a consensus. An expert scientific committee of 15 medical oncologists from India constituted the panel. Twelve clinically relevant questions were grouped into five categories for presentation and discussion: (1) cisplatin and platinum ineligibility criteria; (2) programmed death ligand 1 and fibroblast growth factor receptor (FGFR) testing in mUC patients; (3) treatment options in 1L settings; (4) role of switch maintenance; and (5) treatment options in 2L. Statements that reached high (- 80%) and moderate (60-79%) levels of consensus in the first round (electronic survey) did not undergo the second Delphi round. The questions that received a low level of consensus (< 60%) were discussed during the virtual meeting. Results Renal impairment (creatinine clearance [CrCl]<60mL/min) and New York Heart Association class 3 heart failure are important assessment criteria for determining cisplatin ineligibility. Patients are unfit for any platinum-based chemotherapy in case of Eastern Cooperative Oncology Group performance status> 3 or severe renal impairment (CrCl<30 mL/min). Gemcitabine and platinum with cisplatin over carboplatin were preferred in 1L settings. In patients unfit for cisplatin-based regimens, carboplatin-gemcitabine chemotherapy was preferred over immunotherapy (atezolizumab or pembrolizumab). Selected patients who are platinum ineligible may be considered for immunotherapy. Post-induction chemotherapy, those who do not progress may be strongly considered for avelumab maintenance. Experts recommended erdafitinib in FGFR-positive mUC patients in 2L settings. In FGFR-negative patients, immunotherapy (pembrolizumab, nivolumab, or avelumab)may be preferred over chemotherapy (paclitaxel, docetaxel, or vinflunine). Enfortumab vedotin and sacituzumab govitecan may be considered for further lines of therapy. Conclusion Expert panel consensus will offer expert guidance to oncologists/clinicians on the management of mUC in Indian settings. [ABSTRACT FROM AUTHOR]